Tags

Type your tag names separated by a space and hit enter

Mycobacterium tuberculosis infection and vaccine development.
Tuberculosis (Edinb). 2016 05; 98:30-41.T

Abstract

Following HIV/AIDS, tuberculosis (TB) continues to be the second most deadly infectious disease in humans. The global TB prevalence has become worse in recent years due to the emergence of multi-drug resistant (MDR) and extensively-drug resistant (XDR) strains, as well as co-infection with HIV. Although Bacillus Calmette-Guérin (BCG) vaccine has nearly been used for a century in many countries, it does not protect adult pulmonary tuberculosis and even causes disseminated BCG disease in HIV-positive population. It is impossible to use BCG to eliminate the Mycobacterium tuberculosis (M. tb) infection or to prevent TB onset and reactivation. Consequently, novel vaccines are urgently needed for TB prevention and immunotherapy. In this review, we discuss the TB prevalence, interaction between M. tb and host immune system, as well as recent progress of TB vaccine research and development.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Tang J
AIDS Institute and Department of Microbiology, Research Centre for Infection and Immunity, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.
Yam WC
Department of Microbiology, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region.
Chen Z
AIDS Institute and Department of Microbiology, Research Centre for Infection and Immunity, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region; HKU-AIDS Institute Shenzhen Research Laboratory and AIDS Clinical Research Laboratory, Guangdong Key Laboratory of Emerging Infectious Diseases and Shenzhen Key Laboratory of Infection and Immunity, Shenzhen Third People's Hospital, Guangdong Medical College, Shenzhen, PR China. Electronic address: zchenai@hku.hk.

MeSH

Adaptive ImmunityAnimalsBCG VaccineDrug DiscoveryHost-Pathogen InteractionsHumansImmunity, InnateMycobacterium tuberculosisPrevalenceTuberculosisTuberculosis Vaccines

Pub Type(s)

Journal Article
Review
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27156616

Citation

Tang, Jiansong, et al. "Mycobacterium Tuberculosis Infection and Vaccine Development." Tuberculosis (Edinburgh, Scotland), vol. 98, 2016, pp. 30-41.
Tang J, Yam WC, Chen Z. Mycobacterium tuberculosis infection and vaccine development. Tuberculosis (Edinb). 2016;98:30-41.
Tang, J., Yam, W. C., & Chen, Z. (2016). Mycobacterium tuberculosis infection and vaccine development. Tuberculosis (Edinburgh, Scotland), 98, 30-41. https://doi.org/10.1016/j.tube.2016.02.005
Tang J, Yam WC, Chen Z. Mycobacterium Tuberculosis Infection and Vaccine Development. Tuberculosis (Edinb). 2016;98:30-41. PubMed PMID: 27156616.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mycobacterium tuberculosis infection and vaccine development. AU - Tang,Jiansong, AU - Yam,Wing-Cheong, AU - Chen,Zhiwei, Y1 - 2016/02/27/ PY - 2015/12/28/received PY - 2016/02/22/accepted PY - 2016/5/10/entrez PY - 2016/5/10/pubmed PY - 2017/11/14/medline KW - Bacillus Calmette–Guérin KW - Immune response KW - Mycobacterium tuberculosis KW - Vaccine SP - 30 EP - 41 JF - Tuberculosis (Edinburgh, Scotland) JO - Tuberculosis (Edinb) VL - 98 N2 - Following HIV/AIDS, tuberculosis (TB) continues to be the second most deadly infectious disease in humans. The global TB prevalence has become worse in recent years due to the emergence of multi-drug resistant (MDR) and extensively-drug resistant (XDR) strains, as well as co-infection with HIV. Although Bacillus Calmette-Guérin (BCG) vaccine has nearly been used for a century in many countries, it does not protect adult pulmonary tuberculosis and even causes disseminated BCG disease in HIV-positive population. It is impossible to use BCG to eliminate the Mycobacterium tuberculosis (M. tb) infection or to prevent TB onset and reactivation. Consequently, novel vaccines are urgently needed for TB prevention and immunotherapy. In this review, we discuss the TB prevalence, interaction between M. tb and host immune system, as well as recent progress of TB vaccine research and development. SN - 1873-281X UR - https://www.unboundmedicine.com/medline/citation/27156616/Mycobacterium_tuberculosis_infection_and_vaccine_development_ DB - PRIME DP - Unbound Medicine ER -